Royal Bank of Canada
CLRB icon

Royal Bank of Canada’s Cellectar Biosciences CLRB Stock Holding History

Royal Bank of Canada’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-83
Closed -$10K – 7102
2024
Q1 		$10K Buy
+83
New +$8.99K ﹤0.01% 6192
2021
Q3 		– Sell
-50
Closed -$18K – 7651
2021
Q2 		$18K Buy
50
+17
+52% +$7.37K ﹤0.01% 6610
2021
Q1 		$16K Buy
+33
New +$19.6K ﹤0.01% 6555
2018
Q2 		– Hold
0
– – – 6542
2018
Q1 		– Hold
0
– – – 6380
2017
Q4 		– Hold
0
– – – 6565
2017
Q3 		– Hold
0
– – – 6728

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's CLRB Position: Q2 2024 in Review

Royal Bank of Canada sold out of Cellectar Biosciences (CLRB) in Q2 2024, closing a stake of 83 shares — an estimated $10K sold.

Royal Bank of Canada first reported a position in CLRB in Q1 2021 and held it in 3 quarters. The position peaked at $18K in Q2 2021. 37 funds tracked by Wall St. Rank hold CLRB as of Q2 2024.

  • Royal Bank of Canada reported no remaining Cellectar Biosciences position as of Q2 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 83 Cellectar Biosciences shares in Q2 2024, an estimated $10K.
  • Royal Bank of Canada first reported a position in Cellectar Biosciences in Q1 2021 and held it in 3 quarters.
  • Royal Bank of Canada's Cellectar Biosciences position peaked at $18K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.